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Abstract 
 
 
Opiates have been used for centuries both as recreational drugs and for medical purposes. 
Opioids are substances that bind opioid receptors that are present throughout the nervous 
system. These receptors are the primary mediators of the pharmacological effects of opioids. 
However, their addiction potential is due to their rewarding/reinforcing effects conveyed by 
activation of dopaminergic neurons in the ventral tegmental area (VTA). Activation of VTA 
neurons leads to an increased release of dopamine in the nucleus accumbens (NAc), which is 
an important mechanism related to the reward/reinforcing effect of a variety of drugs and 
natural stimuli. 
  
Heroin is rapidly metabolized to 6-monoacetylmorphine after intake, which is further 
converted to morphine. Morphine is metabolized to morphine-6-glucuronide (M6G) and 
morphine-3-glucuronide (M3G). M6G has recently been showed to have rewarding effects 
similar to morphine, while M3G has not showed such effects. It is well known that morphine, 
has rewarding effects and increase dopamine release in the NAc. The effects of the morphine 
metabolites on mesocorticolimbic dopamine release have not yet been studied. The present 
study thus aims to investigate how morphine, M6G and M3G affect extracellular 
concentrations of dopamine in the NAc by using the in vivo microdialysis technique in freely 
moving mice. Microdialysis samples were analyzed for dopamine by high performance liquid 
chromatography (HPLC) with electrochemical detection (ED) after injection of different 
doses of morphine, M6G and M3G. 
   
Both morphine and M6G treatment significantly increase extracellular dopamine 
concentrations in NAc, but a dose-response relationship was not seen for the two doses used. 
Administration of M3G shows no significant increase in extracellular dopamine. This study 
therefore confirm previous results indicating that M6G, but not M3G, have addictive 
properties and thus might play an important role in development of dependence after heroin or 
morphine administration.  
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1. Introduction 
 
1.1 Opiates 
Opiates are traditionally extracted from the Opium poppy (Papaver somniferum) or produced 
in laboratories as synthetic opioids. Morphine and codeine are examples of natural opiates, 
whereas naloxone and heroin (diacetylmorphine) are semi synthetic opioids produced from 
opium, and methadone is an example of a fully synthetic opioid product. 
  
Opiates have been used for centuries in folk medicine to cure pain, diarrhea, cough and other 
ailments, as well as in religious rituals and as recreational drugs. In modern medicine, opioids 
are mainly used as pain relievers. In either case, used as medicine or recreational drug, 
addiction to opiates is a major problem for the individual as well as the society. Addiction to 
opioids might lead to social problems e.g. criminality, prostitution, diseases, injuries, 
accidents etc. This negative social and individual consequence generates high resource costs 
on both levels. An economic estimate done in the United States in 1996 concluded with a total 
cost of heroin addiction at 21.9 billion US$; from them, 5.2 billion US$ was due to criminal 
activity, 11.5 billion US$ caused by lost productivity, and another 5.0 billion US$ was due to 
medical care costs (Mark et al. 2001). Chronic opioid addiction is still difficult to treat, and 
the relapse percentage is relative high after detoxification and treatment. Therefore, it is 
important to increase our knowledge on the neurological mechanisms that induce and 
maintain opioid addiction, in order to promote the development of more effective treatments. 
 
 
1.1.1 Pharmacology of opiates  
Morphine has been the most used analgesic in modern medicine for decades. When 
administrated to relieve pain, the analgesic effect is prominent. Morphine is also used as a 
recreational drug, with intoxication and hedonia/ euphoria as the more marked effects. The 
pharmacological effect of heroin is also believed to be mediated trough morphine, as one of 
its major metabolites. Heroin is rapidly deacetylated to 6-monoacetylmorphine (6MAM) by 
carboxylesterase-1, carboxylesterase-2 and pseudocholinesterase (CE-1, CE-2 and pseudo-
ChE) bound to the surface of red blood cells among others (Aderjan & Skopp 1997). These 
same enzymes convert further 6MAM to morphine (Maurer et al. 2006; Rook et al. 2006). 
The half life of heroin in human blood is on an average 1.3-7.8 minutes (Rook et al. 2006). 
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Such short half life, besides its poor receptor efficacy (Inturrisi et al. 1983; Rook et al. 2006), 
indicates that heroin itself dos not exert significant pharmacological effects, thus being 
considered as a prodrug exerting its effect through its metabolites. When heroin is used 
clinically or for intoxication purpose, it is preferably administrated parenteral, avoiding the 
complete first-pass metabolism by hepatic and extra hepatic factors. Heroin has a higher 
degree of lipophilicity compared to morphine that leads to a more effective penetration 
through the blood brain barrier (BBB), thereby delivering a more intense and immediate 
pharmacological effect (Oldendor et al. 1972; Inturrisi et al. 1984). The degree of 
involvement of different metabolic pathways depends largely on the route of administration, 
i.e. parenteral or orally. Morphine, either directly administered or formed after metabolism of 
heroin, is further metabolized to morphine-6-glucuronide (M6G) and morphine-3-glucuronide 
(M3G) by uridine diphosphate glucuronyltransferases (UGTs), where UGT2B7 is the major 
contributor (Coffman et al. 1997; Lotsch 2005; Maurer et al. 2006). Morphine is also, but in a 
lesser extent, N-demethylated by hepatic CYP3A4 and CYP2C8 to normorphine, or 
conjugated with sulphate, catalyzed by sulphotransferase or sulphokinase, to morphine-3-
sulphate (M3S) and morphine-6-sulphate (M6S) (Maurer et al. 2006). These metabolites may 
also further be metabolized trough glucuronidation in the same manner as morphine. The 
glucuronated or sulphated morphine compounds are highly hydrophilic, so the main excretion 
is via urine with a minor amount through bile. In humans, the main excretion metabolite is 
M3G, accounting for 50-60 % of excretion, M6G and morphine representing 8-10 % and 5-10 
% respectively. M3S stands for 5-10 %, and normorphine for 1-6 % excretion, including their 
glucuronated conjugates (Aderjan & Skopp 1997; Rook et al. 2006). 
 
 
1.1.2 Opioid receptors 
Opioid receptors have multiple functionalities and are distributed throughout the nervous 
system, both in the central nervous system (CNS) and peripheral nervous system (PNS). 
Opioid receptors are involved in nociception as well as in reward, but also emotional, 
autonomic, neuroendocrine and immunological responses are affected (Kreek et al. 2002; 
Kieffer & Evans 2009). Based on its aminoacid sequence, the opioid receptors are members 
of a lager family of receptor proteins, namely the rhodopsin-like G-proteins. Other members 
of this family are receptors for many peptide neurotransmitters, receptors for the monoamine 
neurotransmitters dopamine, serotonin, adrenaline and noradrenalin, as well as for 
acetylcholine (Kieffer & Evans 2009). The opioid binding sites are within the seven 
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transmembrane helical structure of the receptor protein, which has a relative high homology 
between the different receptor subtypes. The current hypothesis for selectivity for agonist or 
antagonist ligands is that the extracellular N-terminal domains, which are less homologous, 
are functioning as gates that allow entering of their respective ligands (Kieffer & Evans 
2009). Endogenous ligands for opioid receptors are the opioid peptides, like endorphins, 
endomorphins, enkephalins and dynorphins. The receptors are divided into three subtypes 
related to their N-terminal domain and named with the prefix µ (mu), δ (delta), or κ (kappa) 
opioid receptors (also known as MOP, DOP and KOP receptors respectively)(Kreek et al. 
2002; Kieffer & Evans 2009). Opioid receptors are G-protein coupled and the effect of ligand 
binding and activation can initiate different intracellular responses depending on the G-protein 
in function: the Gi subtype protein inhibits the cAMP production pathway, the Gs subtype 
protein stimulates cAMP production, and the Gq subtype activates the phosphoinositol 
signaling pathway. Binding of ligand to receptors induces a conformational change in the 
transmembrane structure, leading to modifications of the intracellular structure of the 
receptor. This initiates the interaction with the G-protein in such a way that it dissociates from 
the activated receptor (Kieffer & Evans 2009). The G-protein, depending of its subtype, may 
further either directly affect potassium ion channels, like the invarding-rectifyng potassium 
channel (Kir3) and G-protein-activated inwardly rectifying potassium channels (GIRKs), 
leading to a hyperpolarization of the neuron, or, act through several second messenger 
systems, having more long term effects on ion channels and/or genomic factors (Lambe & 
Aghajanian 2005; Kieffer & Evans 2009). 
 
 
1.1.3 Pharmacological effects of opioids 
The existence of different opioid receptors throughout the nervous system indicates that there 
are multiple neuronal sites and systems were endogenous or exogenous opioids can modulate 
their effects. Morphine acts principally as a µ-opioid receptor agonist, although it also has 
some activity trough the δ-opioid receptor (1.9%) and κ-opioid receptors (0.6%) (Aderjan & 
Skopp 1997). CNS structures, such as striatum, nucleus accumbens (NAc), diagonal band of 
Broca, globus pallidus, ventral pallidum, bed nucleus of the stria terminalis, medial and 
cortical amygdale, mammillary nuclei, median raphe, locus coeruleus, nucleus of the solitary 
tract and most thalamic nuclei etc, are regions coupled to e.g. reward/reinforcement, 
intoxication, nociception/pain, stress and neurohormone secretion, and have an especially 
high abundance of µ-opioid receptors (Aderjan & Skopp 1997; Koob & Moan 2006; 
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McClung 2006). Upon binding of the ligand, µ-opioid receptors induce hyperpolarization and 
mediate inhibition of neural activity in several of these structures. In relation to the rewarding 
properties of opioids, activation of µ-opioid receptors leads to inhibition of neurones that 
release γ-aminobutyric acid (GABA) and tonically inhibit dopaminergic neurons in the ventral 
tegmental area (VTA). This leads to a surge of dopamine in the NAc and other mesolimbic-
mesocortical brain regions, which is critical for the manifestation of reward (Johnson & North 
1992; De Vries & Shippenberg 2002; Kreek et al. 2002; Luscher & Ungless 2006; Kauer & 
Malenka 2007).        
 
In the nervous system, opioids modulate nociception through activation of peripheral and 
central µ, δ, and κ-receptors. The antinociceptive effect is mediated by at least to mechanisms: 
first, the excitability of the spinal primary neuron receiving the nociceptive input may be 
attenuated; second, the release of excitatory neurotransmitters, such as substance P, from 
afferent neurons may be inhibited by opioid receptor activation (Millan 1986; Stein 1993)  
 
The morphine metabolite M6G is on the break of being introduced in the clinic as an 
analgesic. Its analgesic properties has been subjected for thoroughly investigation and found 
to be equivalent to morphine (Kilpatrick & Smith 2005). M6G has been shown to be 45 times 
as active as an analgesic compared to morphine sulphate when injected intracerebrally into 
mice, and a 37-fold increase with prolonged duration has been observed when given systemic 
(Shimomur et al. 1971; Boerner et al. 1975). M6G has been shown to have an improved side 
effect profile, with a reduced tendency to cause nausea, vomiting, sedation and respiratory 
depression compared with morphine (Kilpatrick & Smith 2005; Maurer et al. 2006). Several 
studies indicate that M6G penetrates the BBB less efficiently than morphine (Aasmundstad et 
al. 1995; Bickel et al. 1996; Aderjan & Skopp 1997; Wu et al. 1997). The transfer half life 
between plasma and effect compartment was determined to be 2.6 houres for morphine and 
8.2 houres for M6G (Skarke et al. 2003; Kilpatrick & Smith 2005). Differences in 
permeability through cell membranes e.g. the BBB for morphine and M6G are believed to be 
associated with the lower lipid solubility of M6G, although differences in active influx and 
efflux by various transport proteins, such as the P-glycoprotein’s, organic anion transporters, 
glucose transporters etc, may also be involved (Aderjan & Skopp 1997; Rook et al. 2006).  
The main differences between M6G and morphine that may be responsible for the different 
pharmacological and toxicological response are summarized by Kilpatrick et al. (2005) as 
follows:  
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• “Morphine has an slightly higher affinity for the µ-opioid receptor than M6G 
• M6G shows slightly higher efficiency at the µ-opioid receptor 
• M6G has a lower affinity for the κ-opioid receptor than morphine 
• M6G has a very different absorption, distribution, metabolism, excretion (ADME) 
profile from morphine with: 
o A lower volume of distribution 
o A lower permeability across the BBB 
o Higher levels achieved in the extracellular compartment of the brain 
o A slow exit from the brain” 
Kilpatrick et al. (2005) also emphasize in their review that there is significant amount of data 
that shows substantial differences between species related to M6G and morphine effects, and 
that extreme care should be taken when extrapolating results from non-primate studies to 
possible human effects. 
 
The pharmacokinetic properties of M3G and M6G are quite similar. Volume of distribution 
(VD) in mice are found to be 0.5, 0.9, and 3.2 l/kg, and clearance (CL) 24, 15, and 80 
ml/min/kg for M3G, M6G, and morphine respectively (Handal et al. 2002). Effects of M3G 
administration in clinical studies have shown to include aversive effects like neuroexcitation 
(e.g. muscle twitches and seizures), hyperalgesia, and allodynia (Skarke et al. 2005; Rook et 
al. 2006). Measurement of locomotor activity after administration of a drug is a widely used 
method to measure psychostimulating properties. Both morphine and M6G has been shown to 
increase locomotion, whereas M3G shows no effect on this behaviour (Handal et al. 2002). 
Studies using the conditioned place preference (CPP) have shown that both morphine and 
M6G can have rewarding effects, whereas M3G shows a tendency to cause aversion 
(Vindenes et al. 2006). M3G has a very low affinity for opioid receptors compared to 
morphine and M6G (Bickel et al. 1996; Skarke et al. 2005), and its antagonistic effects 
compared to morphine and M6G is thus believed to be mediated through other mechanisms. 
This behavioural studies indicates that M6G as morphine may have rewarding properties, 
which would be mediated through increased dopamine release in NAc. Since M3G shows 
such opposite effects on behaviour, it is likely that M3G does not affect the dopamine 
functionality. 
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Opiates have a variety of secondary effects, like nausea, vomiting, sedation, depression of the 
respiratory system, as well as development of tolerance. Depression of the respiratory related 
neurons by agonist activity on µ-opioid receptors and δ-opioid receptors in ventrolateral 
medulla and dorsolateral pons is the main reason for suffocation by overdoses of heroin and 
morphine (Lalley 2008).   
 
 
1.2 The nervous system underlying opioid addiction 
 
1.2.1 The mesocorticolimbic dopamine system 
Most dopamine containing neuron systems develop from an embryonic cell group originating 
at the mesencephalic-diencephalic region of the brain (midbrain dopaminergic neurones), and 
projects to various forebrain structures. One of these systems ,the mesocorticolimbic system, 
consists of two diffuse, overlapping neuronal pathways, the mesolimbic and the mesocortical 
system, originating in the VTA. The mesolimbic system is defined by neurons projecting 
mostly to NAc and olfactory tubercle (ventral striatum), but also with projections to the 
septum, amygdala and hippocampus. On the NAc, these neurons project on GABAergic 
neurons. The mesocortical system originates in the medial VTA, with projections to the 
medial prefrontal, cingulated and perirhinal cortex (Kalivas & Volkow 2004; Kelley 2004; 
Everitt & Robbins 2005; Luscher & Ungless 2006; Pierce & Kumaresan 2006). Neurons in 
the mesolimbic system containing dopamine or dopamine receptors have been shown to be 
involved in rewarding responses to natural reinforcers, such as food, drink, social interaction 
and sex, as well as to several drugs (Wise & Rompre 1989; Nestler 2001a; Kreek et al. 2002; 
Kalivas & Volkow 2004; Wise 2004; Nestler 2005).  
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Figure 1. Blue arrows illustrate dopaminergic afferent projections originating in the VTA. 
The medial forebrain bundle (MFB) is the main circuit involved in reward, VTA and NAc 
lying along this circuit. Not shown in this figure are the glutamatergic and GABAergic 
interneurons also essential for this circuit.  
 
GABAergic neurons on the NAc are activated by cortical inputs, mediated mainly by the 
excitatory neurotransmitter glutamate acting on N-methyl-D-aspartate (NMDA) and α-amino-
3-hydroxyl-5-methylisoxazole (AMPA) receptors. The degree of activity of Glutamate on 
these receptors is the principal source for long-term plasticity, a mechanism essential for 
learning. The coexistence of dopaminergic and glutaminergic innervations on the same 
dendrite spine of the GABAergic neurons is a critical factor for the effects on neural plasticity 
in NAc. Upon activation of both dopamine (D1 subtype), AMPA and NMDA -receptors, a 
cascade of second messenger systems is activated, leading to up- and downregulation of  
numerous genes by different transcription factors like ∆FosB and CREB (cAMP response-
element binding protein) working as coincidence detectors. Eventually, these processes will 
lead to synaptic remodelling together with changes in other effector mechanisms.  (Konradi et 
al. 1996; Hyman & Malenka 2001; Nestler 2001b; Nestler 2001a; Kelley 2004; Nestler 2005).  
 
Glutamate is released as respond to relative specific input from sensory, motor and memory 
circuits. Dopamine in NAc, on the other hand, is released upon unpredicted, rewarding events, 
e.g. food, sex, social interaction, drugs. Thus, the interaction of these two systems are 
essential for the shaping of neural networks associated with learning and memory of natural 
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rewards and/or various drugs, being the time frame of the interaction upon these receptors a 
crucial factor (Kelley 2004). 
 
 
1.2.2 Dopamine and dopamine receptors 
Dopamine is a catecholamine neurotransmitter, as well as an intermediate in the biosynthesis 
of other catecholamines like adrenaline and noradrenalin. The rate limiting step in dopamine 
synthesis is the conversion of L-tyrosine to L-DOPA (3, 4-dihydroxyphenylalanine) by 
tyrosine hydroxylase (TH), with tetrahydrobiopterin (BH4) as cofactor (Venter et al. 1988; 
Kreek et al. 2002). TH is also subject for end-product inhibition by dopamine itself or other 
catecholamines by competing for a binding site with BH4. TH has the property of existing in 
two affinity states, low and high, depending on neural activity and autoreceptor inhibitory 
feedback. This regulation ensures that the synthesis of dopamine is sufficient in activated 
neurons, as well as suppressed when dopamine is released in such amounts that it activates 
autoreceptors. L-DOPA is further converted to dopamine by DOPA decarboxylase, with 
pyridoxal phosphate as cofactor. The whole synthesis takes place in the cytoplasm, and the 
synthesised dopamine is actively transported into vesicles by the vesicular monoamine 
transporter (VMAT). This vesicular storage prevents both degradation by monoamine oxidase 
(MAO) and end-product inhibition of TH (Venter et al. 1988).  
 
Upon neuronal activation, dopamine is released to the synaptic cleft by exocytosis and fusion 
with the synaptic terminal membrane. Released dopamine diffuses in the extracellular space, 
where its concentration is affected by reuptake, metabolism and binding to receptors. 
Dopaminergic receptors are metabotropic and pertain to the same family as the opioid 
receptors cited above (Kieffer & Evans 2009). There are five subtypes, D1 to D5, 
encompassed in two families. The D1 and D5 subtypes are members of the D1-like family, and 
are coupled to Gs proteins, therefore stimulating adenylate cyclise (AC) and leading to an 
increase in cAMP production. The D2, D3, and D4 are constituents of the D2-like family, and 
coupled to Gi proteins, inhibiting AC and cAMP production. The main post synaptic 
dopamine receptors are of the D1 or D2 subtype, the main dopamine presynaptic autoreceptor 
being of the D2 type (Kebabian & Calne 1979; Sokoloff et al. 1990; Sunahara et al. 1991; Van 
Tol et al. 1991; Lambe & Aghajanian 2005). Typical for metabotropic receptors, they work 
by modulatory mechanisms with a relative long delay between ligand-receptor interaction and 
functional changes in the recipient cell. The end result, with mechanisms and effects differing 
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between activation of D1 and D2, is modulation of membrane excitability. A tonic dopamine 
activation of D1 generally increases membrane excitability, whereas D2 receptor activation 
decreases the excitability of the neuron (Venter et al. 1988; Schultz 2002; West & Grace 
2002; Di Chiara & Bassareo 2007).  
 
 
1.2.3 Learning, reward and addiction 
Associative learning of rewarding behaviors is mediated through a cognitive awareness in 
contingency between the action and the outcome which gives a rewarding sensation, which is 
mediated, at least in part, by increased dopamine levels in NAc (Schultz 2002; Kelley 2004). 
Drugs of abuse, also opiates, increase the extracellular levels of dopamine in the same way as 
natural factors such as food and sex, a process evolved for learning habits that increase the 
chance of survival of the subjects. Drugs act directly on these neural circuits involved in 
reward, and much more strongly than natural rewards, also bypassing the feedback 
mechanisms normally controlling dopamine release in NAc after the influence of natural 
rewards or associated cues. By greatly increasing dopamine levels, drugs promote Pavlovian 
incentive learning to drug conditioned stimuli through the neural plasticity mechanisms cited 
above, that is, dopamine and Glutamate activation of D1, AMPA and NMDA receptors on 
neural dendrites in NAc (Kelley 2004; Di Chiara & Bassareo 2007). Repeated opiate use 
alters the activity of GABAergic neurons in NAc that are primary target by afferent dopamine 
and glutamate neurons. These GABAergic efferent neurons, which also contain the opioid 
peptides enkephalin or dynorphin, this last coexisting with substance P, project back upon the 
ventral pallidum and VTA, creating a feed back circuit (De Vries & Shippenberg 2002). 
Alterations in this system may contribute to the aversive consequences of opiate withdrawal 
(Volkow et al. 2008). Evidence for this is that treatment with a dopamine D2 receptor agonist 
reduces opiate withdrawal effects, whereas an antagonist induces withdrawal signs (De Vries 
& Shippenberg 2002; Schultz 2002). A possible molecular mechanism is that activation of D2 
(Gi) receptors on GABAergic neurons in NAc reduce the excitation of these neurons, thus 
reducing GABAergic inhibition of the dopaminergic VTA neurons. An altered (reduced) tonic 
release of dopamine to NAc, as result of chronic drug abuse, will increase the activity of the 
inhibitory effects of GABAergic neurones and mediate withdrawal symptoms (De Vries & 
Shippenberg 2002).    
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1.3 The microdialysis technique 
Brain dialysis was developed during the 1960´s and 70´s to measure extracellular levels of 
neurotransmitters among other substances in vivo. The dialysis technique has provided 
biochemical evidence of the involvement of dopamine in the rewarding effects of drugs of 
abuse like opiates, ethanol, nicotine, cocaine, amphetamines, cannabinoids, MDMA etc. (Di 
Chiara & Imperato 1988; Zocchi et al. 2003; Fadda et al. 2005).  
Microdialysis is an in vivo method extensively used for measurement of endogenous 
neurotransmitters in various brain regions.  A probe with a semi-permeable membrane is 
stereotaxically implanted in the brain and perfused with a solution with similar ionic 
concentration as the cerebral spinal fluid. A concentration gradient is build between the 
extracellular space (ECS) and the inner of the probe, thus small molecules, like the 
neurotransmitters e.g. dopamine, will diffuse through the membrane to the inside of the probe 
following the concentration gradient. By regulating the flow through the probe, collection of 
the dialysis samples are possible and concentrations of neurotransmitters can be later 
measured with, e.g. by high performance liquid chromatography (HPLC) method connected 
to a detector (electrochemical, fluorescent, etc.) (Torregrossa & Kalivas 2008).      
 
 
1.4 Aim of the study 
The introduction in the clinic of M6G as an analgesic, as well as the importance of developing 
new treatments for addictive diseases, emphasize the need for further understanding of the 
underlying neurobiological mechanisms of opioids and their metabolites. The effects of the 
morphine metabolites M6G and M3G on analgesia (Kilpatrick & Smith 2005), locomotor 
activity (Handal et al. 2002), and reward (Abbott & Franklin 1991; Vindenes et al. 2006; 
Vindenes et al. 2008) have already been studied. However, the effect of M6G and M3G on 
mesocorticolimbic dopamine levels has, to our knowledge, not yet been studied. 
  
Rodents metabolize morphine to M3G but not M6G (Wu et al. 1997; Handal et al. 2002), 
making them suitable for studying separately the effects seen after administration of morphine 
and M6G. The C57BL/6 mouse strain is selected for its known sensitivity for morphine, and 
for comparison to other studies done on the same strain at the Norwegian Institute of Public 
Health on effects of morphine, M6G and M3G e.g. (Handal et al. 2002; Fadda et al. 2005; 
Vindenes et al. 2006; Vindenes et al. 2008). Mice are also extensively used as model 
organism for the analysis of effects of a large number of drugs (Handal et al. 2002; Fadda et 
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al. 2005; Vindenes et al. 2006; Vindenes et al. 2008). E.g. did Murphy et al. (2001) perform a 
central study comparing locomotor activity and mesolimbic dopamine release in C57BL/6J 
mice after morphine administration. By using in vivo microdialysis, they showed a correlation 
between these two parameters. This study aims to further investigate the effects and 
participation of M6G and M3G on extracellular dopamine levels in NAc using the 
microdialysis method. 
 
Morphine has well known rewarding properties. We wished to test our hypothesis that M6G, 
like morphine, mediate reward through elevated dopamine levels in NAc, an essential 
mediator of reward. Our second object is showing that M3G has no effect on dopamine levels, 
providing evidence and partly explaining the lack of behavioural changes in locomotion and 
CPP studies. 
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2. Materials and methods 
 
 
2.1 Animals and conditions 
Male C57BL/6 mice (n=49) (Bomholt, Denmark) weighing about 20-30 g with age between 
6-8 weeks, were used. They were housed six mice per cage, with free access to food and 
water. The cages where placed in standard housing environmental conditions, with artificial 
12 hour light:dark cycle, light period from 08:00 to 20:00. Before the experiment, mice were 
left for about one week for acclimatization to their new housing conditions.  
 
After implantation of the guide cannula (see below), the mice were placed individually in a 
special cage in order to avoid damage to the mouse or the implant. Personal experience from 
other scientists revealed that implanted mouse would attack and damage the implant and each 
other if housed together. 
 
The experiments in this study were performed in accordance with the Norwegian regulations 
on animal experimentation (the Norwegian “Animal Welfare Act” and the “Regulation on 
Animal Experimentation”) and after approval by the Norwegian National Animal Research 
Authority.  
 
 
2.2 Surgical procedure 
Mice were weighted and anesthetized with a 10 ml/kg mixture containing 10 mg/ml Ketalar 
and 1 mg/ml Xylazine (corresponding to a dose of 100 and 10 mg/kg respectively) 
administered intraperitoneally (i.p.). The level of sedation during surgery was checked with a 
pinch on the tail or foot and supplemental doses of anesthetic were administered when 
required. Once completely anesthetized, the animal was placed in a stereotaxic apparatus 
(Model 900 with 926 mouse adaptor, David Kopf Instruments, Tujunga, CA, USA), shown in 
figure 3. During the surgical procedure, the body temperature was keep constant at 37.5 ºC by 
a rectal probe connected to a temperature controller (CMA/150, CMA Microdialysis, Solna, 
Sweden) regulating a thermal pad situated under the animals body. The eyes were covered 
with eye salve to reduce the risk of keratitis or other damages to the eyes.  
 
 15
Once the animal was in place, the skull was exposed by making a longitudinal incision trough 
the skin at the upper side of the head, and the skull bone was cleaned with alcohol. The 
elevation of the nose clamp fixing the head was adjusted until lambda (the intersection 
between the lambdoid and the coronal sutures) and bregma (the intersection between the 
sagittal and the coronal sutures) were at the same horizontal plane. A hole in the skull was 
drilled in a dorsal position over the NAc at the following coordinates relative to bregma: 
Anterior (A): + 1.4 mm; Lateral (L): ± 0.8 mm (Paxinos & Franklin 2001). The lateral 
coordinates (right or left) were switched every other operated animal. Skull structures are 
shown for clarification in figure 2. Another cavity was made at a posterior position at the 
contralateral side of the skull relative to the sagittal suture. This cavity was used to fix a screw 
which will help to stabilize the implant. 
  
 
Figure 2. Picture showing the dorsal surface of the mouse skull, with indication of the 
structures used as reference points in this study (Paxinos & Franklin 2001). 
 
 
A holder bar carrying a vertical guide cannula (CMA/7 Guide Cannula, CMA Microdialysis, 
Solna, Sweden) was fixed to the stereotactic manipulator. The guide cannula was lowered 
through the hole into the brain to a coordinate 4.0 mm ventral (V) relative to bregma. Dental 
cement (Dentalon Plus, Heraeus Kulzer Gmbh, Hanau, Germany) was used to fix the guide 
cannula to the skull. The dental cement encompassed also the fixation screw and a bolt for 
connection to a wire (Figure 3). After surgery, the mice were placed in separate cages for at 
least 24 hours for recovery. 
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Figure 3. Mice placed in the stereotaxic apparatus. The head is fixated by ear bars and a nose 
clamp. The dental cement around the implant can be seen over the head. 
 
 
2.3 In vivo microdialysis experiment 
At least 24 h after implantation, each mouse was attached to the microdialysis sampling 
equipment. To ease the connection procedure, the mice were slightly anesthetized using 
approximately 0.08 ml of the anesthetic mixture. After removing the stylet (dummy probe) 
sealing the guide cannula, a CMA 7/1 microdialysis probe (CMA Microdialysis, Solna, 
Sweden), consisting of a 7 mm shaft with a diameter of 240 µm and a 1 mm long 
semipermeable membrane, was inserted through the guide cannula. Once in place, only the 
1mm semi permeable membrane was protruding beyond the guide cannula and entering the 
area of interest (NAc). One end of a 30 cm steel wire was attached to the metallic bolt encased 
in the implant. Both the probe inlet and outlet were connected to the channel ports of a dual 
channel swivel (Model 375/D/22QE, Instech Solomon, Plymouth Meeting PA, USA) attached 
to a multi-axis counter-balanced lever arm (Model SMCLA, Instech Solomon, Plymouth 
Meeting PA, USA) situated at the top of the experimental cage. The other end of the steel 
wire was fastened to a clamp in the swivel, transmitting the movement of the animal to the 
swivel and arm mounting, impeding the twisting of the tubes (figure 4). The inlet channel was 
connected to a syringe infusion pump (CMA 400, CMA Microdialysis, Solna, Sweden) 
containing an artificial cerebrospinal fluid (Ringer´s solution: 148 mM NaCl, 2.7 mM KCl, 
1.2 mM CaCl2, 0.85 mM MgCl2). The outlet channel was likewise connected to a refrigerated 
fraction collector (CMA/170, CMA Microdialysis, Solna, Sweden), were samples were 
collected in glass vials without any preservatives and maintained at 6 ºC during the 
experiment. The pump flow was set to 0.2µl/min, and mice left for conditioning over night.  
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Figure 4. Picture showing a mouse on the 
microdialysis experimental cage with the 
microdialysis probe attached to the pump 
(on the background) and the fraction 
collector (partially seen at the side). The 
multi-axis counter-balanced lever arm with 
the swivel can be seen at the top of the cage. 
 
 
 
 
 
 
 
 
 
2.4 Experimental protocol 
On the following day, the pump flow was increased to 1 µl/min. The fraction collector, chilled 
to 6 ºC, was programmed to let the first 45 min of flow-through go to waste, ensuring that the 
first sampling would not contain solution that had been standing in the probe-swivel loop over 
night. Thereafter four baseline samples were collected during 20 minutes each. Immediately 
after, the mice received their respective treatment and sampling continued with the collection   
of nine 20 minutes samples.  
 
Treatments consisted of either morphine 10 or 30 µmol/kg (n=10 and 9, respectively), M6G 
10 or 30 µmol/kg (n=8 and 6, respectively), M3G 100 µmol/kg (n=9), or physiological saline 
solution (n=7). All treatments were given subcutaneously (s.c.) on the back about 1 cm cranial 
from the tail root.  
 
 
2.5 Chromatographic analysis of brain samples 
After the last sample was collected, the vials with the samples were sealed and transported in 
a chilled container and placed in the HPLC for analysis. 18 µl of each sample were injected  
either on a Dionex Ultimate 3000 HPLC system (Dionex Corporation, Sunnyvale, CA) or on 
a system consisting of an Agilent model 1100 series pump (Agilent, Santa Clara, CA, USA) 
and a CMA/200 autosampler (CMA Microdialysis, Solna, Sweden). In both cases, the mobile 
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phase was composed of 150 mM sodium dihydrogen phosphate, 4.76 mM citric acid, 3 mM 
sodium dodecyl sulphate, and 50 µM EDTA dissolved in 10 % methanol and 15 % 
acetonitrile, adjusted at pH 5.6, and running at a flow-rate of 0.7 ml/min. Separation was 
achieved through a 80 x 3.2 mm ESA silica column HR, filled with 3 µm particles with pore 
size 120 Å and operated at either 30 ºC or room temperature (about 22 ºC). In each HPLC 
system, detection and quantification of DA was accomplished with a Coulochem II 
electrochemical detector (ESA Inc., Chelmsford, MA) using an ESA model 5020 guard cell 
(situated between the pump and the auto-injector) operating at 500 mV, and an ESA model 
5014B analytical cell operating at -100 mV (E1) and 300 mV (E2). Standard calibration 
samples were injected both at the beginning and the end of each analytical sequence. 
Chromatographic data were analysed and integrated with a Dionex Chromeleon 
chromatographic software (version 6.80), using the height of the peaks for quantification.  
 
 
2.6 Histological verification of probe localization 
At the end of the experiment, mice were deeply anesthetized with an i.p. injection of the 
ketamin/xylazine mixture, and detached from the microdialysis equipment, including removal 
of the microdialysis probe. Each mouse was then immediately sacrificed, the brain gently 
separated from the skull and frozen either in a mixture of dry ice and isopentane (temperature 
ca. -78 ºC) or on liquid nitrogen, and stored at -20 ºC. 
 
Brain slices, 12 -14 µm thick, were later obtained using a cryostat HM 550 (Microm 
International GmbH, Walldorf, Germany). The slices were stained with methylene blue.  
Probe location in each brain slice was checked by microscopic analysis and probe positions 
compared in relation to a well known mouse brain atlas by Franklin and Paxinos (2001) 
(figure 5).  
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Figure 5. Methylene blue stained brain slice and the corresponding plate of the atlas (Paxinos 
& Franklin 2001). The track of the implanted probe can be distinguished on the right 
hemisphere, with its lower 1 mm, encompassing the membrane, inside the limits of the NAc. 
 
 
In order to overcome some problems in locating the correct probe position, halfway into the 
experimental period we started to color the probe location. After disconnection from the 
microdialysis equipment and before sacrificing, a microdialysis probe, detached of its dialysis 
membrane, was inserted through the guide cannula. Diluted methylene blue, 2 µl, was 
injected directly into the brain, coloring the location where the probe had been situated during 
the experiment. Thereafter, the procedure followed as explained above. 
 
 
2.7 Drugs 
Morphine hydrochloride was purchased from Norsk Medisinaldepot, Oslo, Norway. 
Morphine-6-ß-D-glucuronide hydrate and morphine-3-ß-D-glucuronide hydrate were 
purchased from Lipomed, Arlesheim, Switzerland. All drugs were diluted in physiological 
saline to a final concentration resulting in an injection volume of 0.01 ml/g mouse weight. 
 
The doses of 10 and 30 µmol/kg morphine and M6G were chosen since previous studies have 
shown effects of such doses in behaviour models on locomotion and/or CPP. M3G dose was 
set at 100 µmol/kg, after experiencing the death and feebleness of several mice after injection 
of the initial doses of 200 and 400 µmol/kg, doses previously used in behaviour models 
(Vindenes et al. 2006).  
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2.8 Data analysis 
In order to compensate for differences in basal levels of dopamine between individual mice, 
dopamine was transformed to the percentage of the average of the last three baseline samples. 
The results were analyzed with Linear Mixed Models, using SPSS 15.0, with drug treatment 
as dependent factor and time as covariate. The mixed model is fitted for repeated data, with 
compound symmetry as covariate matrix model (selected by the lowest Akaike´s information 
criterion).  The significances from “Type III Tests of Fixed Effects” were used to examine the 
overall effect of drug treatment and time, as well as their interaction. The significances from 
the “Estimates of Fixed Effects” were used as test for differences between each treatment 
dose and saline. A significance p-value lower than 0.05 was considered as statistical 
significant.  
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3. Results 
 
 
3.1 Dopamine concentrations 
Measurement of the basal levels of dopamine in NAc gave a mean value of 0.72 ±0.12 pg/µl. 
Saline treatment shows no effect on the extracellular dopamine concentration in NAc 
compared to baseline values (figures 6, 7 and 8).  
 
For the morphine treatment, the mixed model shows a significant interaction between drug 
treatment and time (p<0.001). It also reveals a significant increase of extracellular dopamine 
after morphine 10 and 30 µmol/kg treatments compared to the saline treatment (p<0.001 and 
p<0.017 respectively) (figure 6).  
 
Treatment with M6G 10 and 30 µmol/kg gives the same significant interaction between drug 
treatment and time (p<0.001). Both doses showed a significant increase in extracellular 
dopamine in NAc compared to the saline treatment (p<0.001 and p<0.004 respectively) 
(figure 7).   
 
No significant different main effect on dopamine levels was seen after the treatment with 
M3G 100 µmol/kg (p<0.316). However, there was a significant interaction between treatment 
and time (p<0.008), as well as a significant difference between M3G and saline treatment 
(p<0.011) (figure 8). However, additional 2-tailed t-tests for independent samples for each 
time point did not show any significant difference between M3G and saline treatment. 
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Figure 6. Changes in extracellular concentrations of dopamine (expressed as percentage of 
baseline) after the s.c. administration of saline (brown circles), or 10 µmol/kg (green circles) 
or 30 µmol/kg (dark brown triangles) morphine. Values are mean ±s.e.m. Baseline represents 
the average of the three samples taken before drug administration. 
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Figure 7. Changes in extracellular concentrations of dopamine (expressed as percentage of 
baseline) after the s.c. administration of saline (dark blue circles), or 10 µmol/kg (blue 
circles) or 30 µmol/kg (indigo triangles) M6G. Values are mean ±s.e.m. Baseline represents 
the average of the three samples taken before drug administration. 
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Figure 8. Changes in extracellular concentrations of dopamine (expressed as percentage of 
baseline) after the s.c. administration of saline (brown circles), or 100 µmol/kg (orange 
circles) M3G. Values are mean ±s.e.m. Baseline represents the average of the three samples 
taken before drug administration. 
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3.2 Histological verification of probe localization 
The location of the microdialysis probes was verified in all animals (n=49), and is illustrated 
in figure 9. All probes were located within the NAc, between the antero-posterior coordinates 
+ 0.74 mm and + 1.42 mm relative to bregma (Paxinos & Franklin 2001).      
 
14
2
95
 
Figure 9. Schematic representation of the microdialysis probes with reference to the atlas of 
Paxinos & Franklin. Vertical lines represent the length of the membrane (1 mm).   
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4. Discussion 
 
 
4.1 Purpose 
Morphine is known to increase dopamine levels in the NAc, an effect related to its reinforcing 
effects (Zocchi et al. 2003; Fadda et al. 2005; Kalivas & O'Brien 2008). The purpose of this 
study was to determine if M3G and M6G also have similar effects on extracellular dopamine 
in NAc. This study is a supplement to other studies done at our laboratory using behavioral 
models, like the CPP model (Handal et al. 2002; Vindenes et al. 2006; Vindenes et al. 2008) 
and locomotor activity (Handal et al. 2002; Vindenes et al. 2006; Vindenes et al. 2008), as a 
measurement of the reinforcing and stimulating effects of M3G and M6G, behaviors known 
to be associated to extracellular dopamine levels in NAc.     
 
 
4.2 Choice of method 
Microdialysis is a method which allows researchers to monitor neurochemical changes after 
drug treatment or other interventions. This technique has been widely used to increase the 
knowledge about the neurobiological processes underlying addiction. Torregrossa et al. 
(2008) have published an excellent review emphasizing the importance of the microdialysis 
technique in determination of the ultimate alterations in various neurotransmitter systems, e.g. 
glutamate, GABA, dopamine, and others, involved in addiction. 
 
     
4.3 Opiate metabolites and dopamine release 
The results obtained in this study reveal that M6G, like morphine, increases the extracellular 
levels of dopamine in NAc, whereas M3G treatment does not lead to such an increase. This is 
in accordance with previous observations of a stimulating effect of morphine and M6G, but 
not M3G, on locomotion (Handal et al. 2002; Vindenes et al. Submitted-b), as well as a 
reinforcing effect of morphine and M6G, and a tendency to aversion for M3G in CPP (Handal 
et al. 2002; Vindenes et al. 2006; Vindenes et al. 2008).  
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The increased dopamine observed after morphine treatment is also consistent with 
microdialysis studies done by Fadda et al. (2005) on effects of morphine on extracellular 
dopamine levels in rats, and similar studies by Zocchi et al. (2003) and Murphy et al. (2001) 
on mice. Fadda et al. (2005) observed also increased serotonin (5-HT) levels in NAc, and 
proposed the possible involvement of the serotonergic systems in the behavioral and 
biochemical responses to morphine. Thus, involvement of other neurotransmitter systems can 
also be important for the neurobiological effects of morphine and, probably, its metabolites.  
 
The statistical analysis showed a significant interaction between M3G and time. However, the 
simple visual inspection of the curves (figure 8) shows that the curve for M3G is very close to 
the one for saline, and the significance could be due to the slightly higher values for M3G 
towards the end of the sampling period. That this significant effect could be due to chance can 
be supported by the fact that any of the t-test between M3G and saline values for each time, 
did not reach statistical significance. In an extension of this study, Vindenes et al. further 
completed the investigation with an additional dose of M3G 50 µmol/kg, as well as increasing 
some of the test groups with additional mice. Results are not yet published, but they show a 
decrease in dopamine for the M3G 50 µmol/kg compared to saline. When this dose is 
included in the statistics, the main effect is still not significant for M3G, time and treatment 
interaction continues to be significant, but a no significant effect on dopamine compared to 
saline is observed (Vindenes et al. Submitted-a).    
  
In behavioral studies, a delayed onset of effects has been detected for M6G. Grung et al. 
(1998) observed that the onset of increased locomotion is seen about 5 min later for M6G than 
for morphine, despite both reached the same level after 20 min. And Vindenes et al. (2008) 
experienced that a 15 min delay had to be introduced before conditioning in order to obtain a 
significant CPP for M6G, whereas morphine significantly induced CPP only when 
conditioning was performed immediately after drug injection. This is also in accordance with 
the observed delay of the antinociceptive effect for M6G compared to morphine, as reported 
in pain studies (Bouw et al. 2001; Skarke et al. 2003). The present study did not however 
show a delayed dopamine release for M6G compared to morphine, as would be expected from 
the behavioral studies cited above. This discrepancy can be explained by limitations in this 
microdialysis model. As a consequence of the extremely low quantity of dopamine in the 
extracellular fluid, the sample period had to be set to 20 min for acquiring a satisfying sample 
amount for analysis, a time period longer than the delay observed in the behavioral effects. A 
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shorter sampling interval possibly would have captured important information about the onset 
of dopamine release, especially in the first 20 min. The levels of dopamine after both 
morphine and M6G treatment also increase continuously throughout the 180 min measured. 
This is long after the maximal increase in the locomotor activity observed in mice (Handal et 
al. 2002). It may have been convenient to extend the experimental time to capture a possible 
drop in dopamine levels for comparison with the decreased locomotion and CPP over time. 
The results for M3G in this study are also consistent with behavioral studies. No effects of 
M3G have been seen either in locomotion studies or CPP studies, but a tendency to aversion 
was seen in the CPP model (Handal et al. 2002; Vindenes et al. 2006).  
 
 
4.4 Methodological challenges 
Several mice died, or noticeable feebleness was seen, after injections of M3G 200 and 400 
µmol/kg, which were the initial doses chosen for M3G.  No such effects were seen in previous 
behavioral studies using up to 500 µmol/kg M3G (Handal et al. 2002; Vindenes et al. 2006). 
We assume that the surgical procedure and implantation of the microdialysis probe in some 
way affects the fitness of the animal and reduces the threshold for toxic effects. M3G has been 
shown, clinically and experimentally, to have neuroexcitatory side effects resulting in 
allodynia, myoclonus and seizures (Smith 1998).   
 
At the beginning of the experiment, we experienced a disagreement between our results and 
similar studies on the effect of morphine on the dopamine response. After a thorough revision 
of the procedure, we concluded that a hypotonic perfusion solution, with a 10 times lower 
ionic concentration, had been used instead the customary physiological, isotonic solution. 
Robinson and Justice (Robinson & Justice 1991) emphasize the importance of using a 
perfusion solution which is as close as possible to that of the extracellular fluid with regard to 
the most important electrolytes. A hypotonic solution would much likely create a 
concentration gradient between the probe and extracellular fluid (ECF), thus draining the ECF 
of ions. This will cause an ionic imbalance at the neuronal membranes, affecting the neuronal 
activity and neurotransmitter release. This process would likely take place immediately after 
initiating the perfusion, that is, already the night before sampling. Figures 10 to 13 show the 
difference in the results between the hypotonic solution and the physiological correct solution 
used there after.       
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Figure 10. Changes in extracellular concentrations of dopamine (expressed as percentage of 
baseline) after the s.c. administration of saline in animals with the microdialysis probe 
prefunded with either hypotonic buffer (continuous line) or physiological isotonic solution 
(dashed line).Values are mean ±s.e.m. Baseline represents the average of the three samples 
taken before drug administration. 
 
 
Figure 11. Changes in extracellular concentrations of dopamine (expressed as percentage of 
baseline) after the s.c. administration of morphine 10 µmol/kg (open circles) or 30 µmol/kg 
(closed circles) in animals with the microdialysis probe prefunded with either hypotonic 
buffer (continuous line) or physiological isotonic solution (dashed line).Values are mean 
±s.e.m. Baseline represents the average of the three samples taken before drug 
administration. 
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Figure 12. Changes in extracellular concentrations of dopamine (expressed as percentage of 
baseline) after the s.c. administration of M6G 10 µmol/kg (open circles) or 30 µmol/kg 
(closed circles) in animals with the microdialysis probe prefunded with either hypotonic 
buffer (continuous line) or physiological isotonic solution (dashed line).Values are mean 
±s.e.m. Baseline represents the average of the three samples taken before drug 
administration. 
 
  
Figure 13. Changes in extracellular concentrations of dopamine (expressed as percentage of 
baseline) after the s.c. administration of M3G 100 µmol/kg in animals with the microdialysis 
probe prefunded with either hypotonic buffer (continuous line) or physiological isotonic 
solution (dashed line).Values are mean ±s.e.m. Baseline represents the average of the three 
samples taken before drug administration. 
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5. Conclusion 
 
 
The results obtained in this study show that, in concordance with our hypothesis, M6G, like 
morphine, increases the extracellular levels of dopamine in NAc, while M3G treatment does 
not lead to such an increase. Since dopamine release on this area has been closed related to 
the reinforcing and rewarding effects of drugs of abuse, this study confirms previous results 
revealing rewarding properties of M6G similar to morphine. Therefore, M6G may have 
addiction potential and may contribute to the development of addiction and dependence of 
heroin and morphine.  
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